GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
Nelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.
comments(0)
5-min edit window · permanent after that